These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20356584)

  • 1. Letrozole monotherapy in the treatment of uterine myomas.
    Ferrero S; Venturini PL; Remorgida V
    Fertil Steril; 2010 May; 93(7):e31; author reply e32. PubMed ID: 20356584
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial.
    Sayyah-Melli M; Mobasseri M; Gharabaghi PM; Ouladsahebmadarek E; Rahmani V
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():257-264. PubMed ID: 28076829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study.
    Leone Roberti Maggiore U; Scala C; Venturini PL; Ferrero S
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():157-62. PubMed ID: 25150954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study.
    Bizzarri N; Ghirardi V; Remorgida V; Venturini PL; Ferrero S
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():22-6. PubMed ID: 26142912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of symptomatic uterine leiomyoma with letrozole.
    Gurates B; Parmaksiz C; Kilic G; Celik H; Kumru S; Simsek M
    Reprod Biomed Online; 2008 Oct; 17(4):569-74. PubMed ID: 18854113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
    George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
    Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women.
    Duhan N; Madaan S; Sen J
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):329-32. PubMed ID: 24103533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.
    Attilakos G; Fox R
    J Obstet Gynaecol; 2005 Aug; 25(6):609-10. PubMed ID: 16234156
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study.
    Brito LG; Candido-dos-Reis FJ; Magario FA; Sabino-de-Freitas MM
    Ultrasound Obstet Gynecol; 2012 Jul; 40(1):119-20. PubMed ID: 22102490
    [No Abstract]   [Full Text] [Related]  

  • 11. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
    Hilário SG; Bozzini N; Borsari R; Baracat EC
    Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
    Russell CA
    Manag Care Interface; 2007 Sep; 20(9):30-1, 36. PubMed ID: 18161388
    [No Abstract]   [Full Text] [Related]  

  • 13. Letrozole (Femara).
    Gerken P
    Clin J Oncol Nurs; 2004 Jun; 8(3):314-5. PubMed ID: 15208828
    [No Abstract]   [Full Text] [Related]  

  • 14. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
    Giannessi PG
    Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
    [No Abstract]   [Full Text] [Related]  

  • 15. Letrozole in breast cancer.
    Hellman S; Hellman D
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971060
    [No Abstract]   [Full Text] [Related]  

  • 16. [The ATAC study on adjuvants in breast cancer].
    Bravi S
    Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
    [No Abstract]   [Full Text] [Related]  

  • 17. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
    Angiolini C
    Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
    [No Abstract]   [Full Text] [Related]  

  • 19. Letrozole in ovulation induction: time to make decisions.
    Polyzos NP; Mauri D; Tzioras S
    Hum Reprod Update; 2009; 15(2):263-4. PubMed ID: 18987099
    [No Abstract]   [Full Text] [Related]  

  • 20. Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole.
    Wang X; Tangjitgamol S; Liu J; Kavanagh JJ
    Int J Gynecol Cancer; 2005; 15(6):1243-8. PubMed ID: 16343224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.